Abstract:Atherosclerosis is a chronic, multifactorial inflammatory disorder of large and medium-size arteries, which is the leading cause of cardiovascular mortality and morbidity worldwide. Although platelets in cardiovascular disease have mainly been studied for their crucial role in the thrombotic event triggered by atherosclerotic plaque rupture, over the last two decades it has become clear that platelets participate also in the development of atherosclerosis, owing to their ability to interact with the damaged arterial wall and with leukocytes. Platelets participate in all phases of atherogenesis, from the initial functional damage to endothelial cells to plaque unstabilization. Platelets deposit at atherosclerosis predilection sites before the appearance of manifest lesions to the endothelium and contribute to induce endothelial dysfunction, thus supporting leukocyte adhesion to the vessel wall. In particular, platelets release matrix metalloproteinases, which interact with protease-activated receptor 1 on endothelial cells triggering adhesion molecule expression. Moreover, P-selectin and glycoprotein Ibα expressed on the surface of vessel wall-adhering platelets bind PSGL-1 and β2 integrins on leukocytes, favoring their arrest and transendothelial migration. Platelet–leukocyte interactions promote the formation of radical oxygen species which are strongly involved in the lipid peroxidation associated with atherosclerosis. Platelets themselves actively migrate through the endothelium toward the plaque core where they release chemokines that modify the microenvironment by modulating the function of other inflammatory cells, such as macrophages. While current antiplatelet agents seem unable to prevent the contribution of platelets to atherogenesis, the inhibition of platelet secretion, of the release of MMPs, and of some specific pathways of platelet adhesion to the vessel wall may represent promising future strategies for the prevention of atheroprogression. Article published online: 19 November 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease

Regulation on RhoA in Vascular Smooth Muscle Cells under Inflammatory Stimulation Proposes a Novel Mechanism Mediating the Multiple-Beneficial Action of Acetylsalicylic Acid

Current concepts and novel targets for antiplatelet therapy

Inhibition of platelet activation and aggregation

Platelet Implication in Atherosclerosis Pathogenesis

Latest Evidence in Personalized Antiplatelet Therapy in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Platelets as therapeutic targets to prevent atherosclerosis

Platelets, a Key Cell in Inflammation and Atherosclerosis Progression

Inflammatory Mediators of Platelet Activation: Focus on Atherosclerosis and COVID-19

Novel Aspects Targeting Platelets in Atherosclerotic Cardiovascular Disease—A Translational Perspective

Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis

Platelet Biology and Implications for Antiplatelet Therapy in Atherothrombotic Disease

The Role of Platelets in Atherosclerosis: A Historical Review

Inflammation and Thrombosis in Coronary Atherosclerosis: Pathophysiologic Mechanisms and Clinical Correlations

Hypercholesterolemia and inflammation—Cooperative cardiovascular risk factors

Clinical pharmacology of antiplatelet drugs

Inflammatory Cytokines and Atherosclerotic Plaque Progression. Therapeutic Implications

A New Therapeutic End for Atherosclerotic Cardiovascular Disease

Biomarkers of Atherosclerotic Plaque Vulnerability and Their Clinical Significance

Role of inflammation and evidence for the use of colchicine in patients with acute coronary syndrome